Building India's precision liquid biopsy company.

Why now

Prostate cancer is rising in India as the population ages, and most diagnoses still rely on PSA followed by biopsy. Liquid biopsy is changing cancer care worldwide, but most tests are priced and designed for Western markets. Mirnow is building tests for Indian patients, clinicians and costs.

Why Mirnow

• Science-led team

  Peer-reviewed publications in miRNA biology, exosomes and medical ML.

• Prospective multicentre validation

  Under way at leading Indian institutions.

• Capital-efficient platform

  Standard RT-qPCR instruments and one ML backbone across indications.

• Protected IP

  Patent application filed; proprietary assay and model.

• Clear path to market

  Central laboratory service first, then kit-based products for diagnostic labs.

• Strong clinical network

  Among urologists and uro-oncologists.